Newsletter · · Ashutosh Agarwal

Lilly Posts a Record Quarter as Novo Reverses Course on Synthetic Semaglutide - Week of August 10, 2026

For the week of August 3 to 10, 2026, Eli Lilly's two big drugs did roughly $15 billion in three months and pushed full-year guidance toward $87 billion, retatrutide posted up to 23% weight loss in late-stage trials, and Novo Nordisk began courting Chinese manufacturing for the synthetic semaglutide it spent years fighting.

Novo Nordisk & Eli Lilly

Week of August 10, 2026: Lilly Posts a Record Quarter as Novo Reverses Course on Synthetic Semaglutide

If you wanted one week that captured where the obesity-drug race actually stands, this was it. Eli Lilly reported a quarter so large it had to raise its full-year forecast, then quietly spent almost all the cash buying up other companies' science. Its next drug posted weight-loss numbers that used to require surgery. And its great rival, Novo Nordisk, spent years telling everyone that lab-made copies of its blockbuster were dangerous, only to start quietly shopping for exactly that in China. The gap between first and second place is turning into a canyon.

TL;DR

  • Lilly's two big drugs did roughly $15 billion in three months and the company lifted its full-year revenue outlook to as much as $87 billion. It is now taking about 61% of the US obesity-and-diabetes drug market versus Novo's 39%.
  • Retatrutide, Lilly's next-generation shot, delivered up to 23% weight loss (about 53-56 pounds) in late-stage trials, plus a 37% drop in triglycerides, efficacy that clinicians on one podcast said is edging into bariatric-surgery territory.
  • Novo is reversing itself on synthetic semaglutide and looking hard at China, at the same moment Pfizer is quietly dropping its obesity drugs entirely. The pecking order below Lilly is getting reshuffled in real time.

What's new

Lilly printed money, then spent it on more science. On the Elon Musk Podcast (a two-host business explainer, 2026-08-07), the hosts walked through a quarter with roughly $23 billion in revenue and net income up $1.5 billion to $7.1 billion. Mounjaro (the diabetes version) rose 91% and Zepbound (the weight-loss version) came in near $4.93 billion; together the two drugs are about 65% of the entire company. Management raised full-year revenue guidance by $3 billion, to as much as $87 billion. But adjusted profit guidance barely moved, because Lilly took a $2.78 billion charge for buying early-stage drugmakers (Orna, Ajax, Sintessa, Colonia), versus just $154 million a year earlier. As one host put it, "Lilly is basically buying probability and risk-adjusted options." Why it matters: this is a company deliberately trading near-term profit to lock up manufacturing and pipeline so no one can catch it.

The headline number, and the one blemish. On The Rundown (a markets recap, 2026-08-06), the host tallied Mounjaro at $9.9 billion (+91%) and Zepbound at $4.9 billion (+46%), "almost $15 billion in sales in just three months", with international Mounjaro up 172% on demand from China, India and Brazil. The one soft spot: orforglipron, Lilly's new oral weight-loss pill, did about $98 million against roughly $103 million Wall Street wanted, with the launch trailing Novo's own pill. Investors shrugged; the stock rose about 5%. The host's blunt summary of the rivalry: "this might be a generational fumble by Novo Nordisk."

Retatrutide's numbers are almost hard to believe. The clearest, most credible read came from clinicians, not analysts. On Diabetes Dialogue (2026-08-04), diabetes specialists Diana Isaacs and Natalie Bellini broke down the Phase 3 (late-stage) results for retatrutide, Lilly's "triple agonist", a drug that hits three gut-hormone targets instead of the usual one or two. In TRIUMPH-3, adults with obesity and existing heart disease lost 22-23% of their body weight (about 53-56 pounds) versus 3% on placebo, and the highest dose cut triglycerides (a blood fat tied to heart risk) by 37%. "We struggle with getting triglycerides to go down and I could do it with 37 percent. Are you kidding me?" Isaacs said. In TRIUMPH-2, patients who also had type 2 diabetes lost up to 21% and saw blood-sugar (A1C) drop 1.4-1.6 points from an already-low starting point. Why it matters: an earlier trial hit 28.3%, which the hosts noted is "close to 30%, like bariatric surgery range." The honest caveat they flagged: the study wasn't long enough to prove the drug prevents actual heart attacks and strokes, that "trend toward improvement... was not statistically significant."

Novo does a U-turn on the very thing it fought. On On The Pen GLP-1 News (a specialist obesity-drug show, 2026-08-04), the hosts laid out a genuine reversal. For years Novo argued that synthetic, lab-made copies of semaglutide (the ingredient in Wegovy and Ozempic) risked immune reactions and quality problems; it sued compounding pharmacies and lobbied regulators to shut them down. Now, according to reports out of Denmark, Novo's leadership has been spending time in China and is close to a manufacturing partner, and is seriously weighing making synthetic semaglutide itself. The reason is a real bottleneck: Novo brews semaglutide using a slow, labor-heavy yeast process, and its new Wegovy pill needs roughly 10 times as much drug per day as the weekly shot. Why it matters: the company that owns the moral high ground on "real" semaglutide may be about to abandon it because it cannot make enough the old way.

Employers are the ones actually paying, and starting to speak up. On Morning Brew Daily (2026-08-07), the hosts relayed Bank of America CEO Brian Moynihan's disclosure that the bank now spends "about $250 million or more" a year covering these drugs for employees, "up from zero four or five years ago", roughly 13% of its entire $2 billion health bill. Just over a third of global employers cover the drugs at all. Why it matters: Lilly and Novo have been begging employers to pay; every big name that says yes widens the market.

The debate

Both sides genuinely showed up this week.

The bull case (well represented). On Halftime Report (2026-08-04), the panel called Lilly a "must-own trillion-dollar" name, "dominant over Novo Nordisk and gaining significant market share," and flagged more than 30% revenue growth with 50% growth in the obesity franchise and further drug approvals as catalysts. On Schwab Network (2026-08-06), strategist Phil Rosen of ProCap Financial predicted Lilly could become the first $2-3 trillion pharma company and keep growing earnings north of 20% a year. On Full Signal (2026-08-04), a veteran investor argued Lilly's results are "much superior" and that once retatrutide is approved, Lilly will lean on its patents to shut down the compounders for good. The through-line: best drugs, most capacity, deepest pipeline.

The bear case (quieter, but real). The skeptics didn't get a dedicated episode, but the worries surfaced inside the bullish coverage, which is more honest than a manufactured counterpoint. First, price: worldwide, Lilly's realized prices fell 13% even as volume jumped 60%, and international prices cratered 36% once Mounjaro joined China's national reimbursement list. As the Elon Musk Podcast framed it, "you're trading pricing power for access to a billion-person market", great for volume, tougher on the price per script over time. Second, concentration: two drugs are ~65% of the whole company, so any manufacturing or safety stumble hits hard. Third, the oral pill's modest launch is a reminder the next chapter (cheaper pills, not shots) is still unproven for Lilly. None of this dented the quarter, but it's the list a careful investor keeps.

The names in play

  • Eli Lilly (LLY), the clear winner of the week: record quarter, raised guidance, ~61% market share, and retatrutide data that expands the story from weight loss into heart disease, sleep apnea and joint pain. Registration filings are reportedly complete across those indications. The label-expansion logic, per the Elon Musk Podcast: "asking an insurance provider to cover a treatment that prevents a knee replacement is a very different conversation than a drug strictly for weight loss."
  • Novo Nordisk (NVO), guiding revenue down about 6% while Lilly grows ~48%, and now reversing its stance on synthetic semaglutide. The China pivot could fix its supply problem or dilute the "premium, safe" brand it spent years building.
  • AstraZeneca (AZ), a credible fast-follower voice. On At Barron's (2026-08-06), CFO Aradhana Sarin said AZ has an oral small-molecule GLP-1 (not a peptide like the others) with Phase 2 data coming and Phase 3 next, and that only "one competitor ahead of us" has an oral drug. Its twist: pairing GLP-1s with treatments for related conditions like high blood pressure and high cholesterol to treat "the patient holistically." It's a plank of AZ's push toward $80 billion of revenue by 2030.
  • Pfizer (PFE), moving the other way. On On The Pen, the hosts detailed Pfizer discontinuing two obesity programs from its $10 billion MetSera acquisition, plus a separate GIP-blocking candidate, after earlier abandoning its danuglipron pill. A big-pharma retreat from the field.
  • Amgen (AMGN), its MariTide drug (Phase 3) works by blocking the GIP hormone rather than activating it like Lilly's drugs do; both somehow drive weight loss. On The Pen was skeptical, citing persistent "vomiting" side effects. Halftime Report saw possible "upside" from Amgen's entry.

Read-throughs

  • Surgical robotics and bariatric surgery (Intuitive Surgical, ISRG). On Brew Markets (2026-08-06), host Anne Berry cited an analyst note that Intuitive's weight-loss surgery volumes fell "high single digits" last quarter as patients slim down on drugs instead of going under the knife. The offset: total da Vinci procedures still grew 15% year over year, with newer uses (cardiac bypass, certain mastectomies) up 40%. So the GLP-1 dent is real but small against a much bigger machine. Quarter revenue was $2.9 billion (+19%).
  • Cold-chain logistics. On InvestTalk (2026-08-04), hosts Justin Klein and Luke Guerrero noted the injectable drugs are temperature-sensitive and need refrigerated shipping end to end, a possible nudge for parcel carriers like UPS and FedEx, though they doubted it moves the needle for those giants and warned against confusing it with cold-storage warehouses.
  • Packaged food. The worry is still there but vague. On Barron's Streetwise (2026-08-07), Jack Hough noted "investors are a little down on snacks at the moment... They're worried about the GLP-1 drugs and demand", sentiment, not hard penetration math this week.

What changed

Two shifts this week are worth marking, because they alter the map below Lilly. Novo publicly softened on synthetic semaglutide, the thing it built a legal and lobbying campaign against, and is courting Chinese manufacturing. And Pfizer effectively exited, dropping the obesity assets it paid $10 billion to acquire. A year ago the story was "who challenges Lilly and Novo." This week it looked more like Lilly pulling away, Novo scrambling to fix its supply, and the deep-pocketed challengers either years behind (AstraZeneca, Amgen) or walking off the field (Pfizer).